JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brewer, G. J.
Right arrow Articles by Wang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brewer, G. J.
Right arrow Articles by Wang, Y.

Journal of the American College of Nutrition, Vol 12, Issue 1 26-30, Copyright © 1993 by American College of Nutrition

JOURNAL ARTICLE

Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents

G. J. Brewer, V. Yuzbasiyan-Gurkan, V. Johnson, R. D. Dick and Y. Wang
Department of Human Genetics, University of Michigan, Ann Arbor 48109-0618.

Zinc (Zn) is increasingly being used as a treatment for Wilson's disease. Some physicians have been prescribing Zn in conjunction with other anticopper agents, such as penicillamine or trien, although theoretically these drugs might be antagonistic in their effects. In addition, Wilson's disease patients quite often take vitamin C in high doses in conjunction with Zn therapy, and there are indications of possible interactions among vitamin C, Zn and copper (Cu). Interactions of penicillamine, trien, and vitamin C with Zn have not been previously studied in terms of the potential effects of these agents on Zn efficacy in Wilson's disease. Here we have studied these interactions in the maintenance phase of therapy, using Cu balance and absorption of orally administered 64Cu as endpoints. We find evidence for probable interactions of both penicillamine and trien with Zn; however, the end result on Cu balance is about the same with Zn alone as it is with Zn plus one of the other agents. Thus, there appear to be no advantages to concomitant administration. We find no detectable interaction of Zn and vitamin C on Cu balance, when vitamin C is taken in daily doses of 1000 mg.


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
G. J. Brewer
Recognition, Diagnosis, and Management of Wilson's Disease
Experimental Biology and Medicine, January 1, 2000; 223(1): 39 - 46.
[Abstract] [Full Text]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
A R. o. t. ANPA Committee on Research, E. C. Lauterbach, J. L. Cummings, J. Duffy, C. E. Coffey, D. Kaufer, M. Lovell, P. Malloy, A. Reeve, D. R. Royall, et al.
Neuropsychiatric Correlates and Treatment of Lenticulostriatal Diseases: A Review of the Literature and Overview of Research Opportunities in Huntington's, Wilson's, and Fahr's Diseases
J Neuropsychiatry Clin Neurosci, August 1, 1998; 10(3): 249 - 266.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American College of Nutrition.